Clinical trials: Adalimumab
Healthy Participants
A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions
A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under…
- Trial name
- NCT07147257
- Testing
- CHS-1420, HUMIRA®
- Where
- China
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Healthy Subjects
Pharmacokinetics and Safety Study of LBAL in Healthy Subjects
To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those of Humira®.
- Trial name
- NCT02206867
- Testing
- LBAL, Humira
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Rheumatoid Arthritis
Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents
This study was conducted to examine the safety profile and the effectiveness in daily clinical practice of adalimumab in rheumatoid arthritis participants showing rapid progression of structural damage of the joints, who had no…
- Trial name
- NCT01783730
- Volunteers
- 163 people
- Sponsor
- AbbVie
Crohn's Disease
Special Investigation (Long-term Investigation) in Patients With Crohn's Disease
This study of Humira will be conducted to obtain information on the safety (especially profile of malignant tumors and serious infections) and effectiveness in patients with Crohn's disease who are receiving Humira for a long…
- Trial name
- NCT01464333
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Abatacept Versus Adalimumab Head-to-Head
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
- Trial name
- NCT00929864
- Testing
- Abatacept, Adalimumab
- Where
- 83 sites in United States, Argentina and 3 more
- Volunteers
- 869 people
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350.
- Trial name
- NCT02983227
- Testing
- GDC-0853
- Where
- 104 sites in United States, Argentina and 8 more
- Volunteers
- 496 people
- Sponsor
- Genentech, Inc.
Hidradenitis Suppurativa
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
- Trial name
- NCT03248531
- Testing
- Bimekizumab, Adalimumab
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- UCB Biopharma SRL
Ulcerative Colitis
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.
- Trial name
- NCT04882683
- Testing
- Prednisone, Azathioprine, Adalimumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Ankylosing Spondylitis (AS), Psoriasis
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
- Conditions
- Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA)
- Trial name
- ADMIT (NCT03339089)
- Where
- 10 sites in China
- Volunteers
- 224 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients
This was an open-label, Phase 2 study designed to obtain user experience data (Phase A) and injection time data (Phase B) in experienced adalimumab patients injected with the Physiolis pre-filled syringe and autoinjector used to…
- Trial name
- NCT01163617
- Testing
- Adalimumab delivered in current syringe, Adalimumab delivered in Physiolis syringe, Adalimumab delivered in current autoinjector
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in Japanese subjects with Crohn's Disease.
- Trial name
- NCT01958827
- Testing
- Adalimumab
- Volunteers
- 28 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an…
- Trial name
- OPAL BROADEN (NCT01877668)
- Testing
- Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab
- Where
- 123 sites in United States, Australia and 14 more
- Volunteers
- 422 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population
This Post-Marketing Observational Study (PMOS) was conducted to assess the effectiveness of adalimumab on reducing synovitis (inflammation of the synovial membrane, which lines movable synovial joints, such as shoulders, elbows…
- Trial name
- NCT01782469
- Volunteers
- 16 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
The study is designed as a prospective, observational study to assess the effect of adalimumab on health-related quality of life (QoL) and work productivity in patients with rheumatoid arthritis (RA) in Taiwan.
- Trial name
- ROCKI (NCT02616380)
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa
Study PTM-001-01 is a 12-week, randomized, placebo controlled, double blind study with a 12 week open-label extension to examine the immunomodulatory activity of PTM-001 in participants with Hidradenitis Suppurativa (HS).
- Trial name
- NCT05020730
- Testing
- PTM-001
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Phoenicis Therapeutics
Rheumatoid Arthritis
Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
This study is a non-confirmatory post-marketing observational study to explore and describe the effectiveness of adalimumab on rheumatoid arthritis (RA) treatment course and participant satisfaction over time in context with…
- Trial name
- PASSION (NCT01383421)
- Volunteers
- 1,036 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Axial Spondyloarthritis
A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)
This study is a non-interventional, longitudinal and non-confirmatory study to compare an active supervised training (AST) with standard of care (SOC) physiotherapy in patients with axial spondyloarthritis and stable response to…
- Trial name
- Treat & Train (NCT03258814)
- Testing
- Active Supervised Training (AST), Standard of Care (SOC) Physiotherapy
- Where
- 6 sites in Germany
- Volunteers
- 17 people
- Sponsor
- AbbVie
Arthritis, Arthritis, Rheumatoid
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
The purpose of this study is to evaluate the efficacy and safety of switching rheumatoid arthritis (RA) participants who have an inadequate response to their current treatment with either etanercept + methotrexate or adalimumab +…
- Conditions
- Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
- Trial name
- NCT01004432
- Testing
- Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX)
- Where
- 117 sites in United States, Austria and 6 more
- Volunteers
- 433 people
- Sponsor
- Janssen Biotech, Inc.